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Abstract This “opinion article” is an attempt to take an
overview of some significant changes that have happened
in our understanding of cancer status during the last half
century and its evolution under the progressive influence
of molecular biology. As an active worker in cancer re-
search and developmental biology during most of this
period, I would like to comment briefly on these changes
and to give my critical appreciation of their outcome as
it affects our knowledge of cancer development as well
as the current treatment of the disease. A recall of my
own contribution to the subject is also included. Two
subjects are particularly developed: cell injury and cell-
killing therapies. Cell injury, whatever its origin, has ac-
quired the status of a pivotal event for the initiation of
cancer emergence. It is postulated that cell injury, a po-
tential case of cellular death, may also be the origin of a
process of stepwise cell reversion (retrodifferentiation or
retroprogrammation) leading, by division, mature or stem
cells to progressive immaturity. The genetic instability
and mutational changes that accompanies this process
of cell injury and rejuvenation put normal cells in a
status favourable to neoplastic transformation or may
evolve cancer cells toward clones with higher malignant
potentiality. Thus, cell injury suggests lifestyle as the
major upstream initiator of cancer development although
this not exclude randomness as an unavoidable contrib-
utor to the disease. Cell-killing agents (mainly cytotoxic
drugs and radiotherapy) are currently used to treat can-
cer. At the same time, it is agreed that agents with high
cell injury potential (ultraviolet light, ionising radiations,
tobacco, environmental pollutants, etc.) contribute to the
emergence of malignant tumours. This represents a real
paradox. In spite of the progress accomplished in cancer
survival, one is tempted to suggest that we have very
few chances of really cure cancer as long as we contin-
ue to treat malignancies with cell-killing therapies. In-
deed, the absence of alternatives to such treatments jus-
tifies the pursuit of current procedures of cancer care.
But, this should be, precisely, an urgent stimulus to
explore other therapeutic approaches. Tumour reversion,
immunotherapy, stem cell management and genomic
analysis of embryo-foetal development could be, among
others, appropriated candidates for future active
research.
Keywords Cell injury . Retrodifferentiation . Foetal
characteristics of cancer . Tumour heterogeneity . Steam cells
andcancerstemcells .Genomicanalysis .Cellkilling therapies
Biology beyond the gene
Fifty years of brilliant success, from the discovery of the
helical structure of DNA to the sequencing of the human
genome, has made molecular biology an irreplaceable par-
adigm of biological sciences. Nevertheless, the molecular
analysis of living processes has shown its limitations. In
the course of an open talk about “biology beyond the
gene” (Le Monde, 25 September 2004) between François
Jacob, Nobel prize winner in Physiology and Medicine
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(1965) and Pierre Sonigo, Laboratory Director at the
Institut Cochin (Paris), an agreement was gained on the
statement that modern Biology has failed “to elucidate the
true essence of living matter” and also failed “to work out
the therapeutic tools able to solve the challenges opened
up by modern Medicine” (see also “The Myth of Biotech-
nology Revolution” [1]).
Eleven years later, the same analysis remains valid. We
do not know how to cure cancer nor the great majority of
degenerative diseases such as diabetes, obesity, cystic fi-
brosis, Alzheimer’s disease, Parkinson’s disease and many
others. However, things have improved and we know how
to treat them with varying success. The terms “successful
treatment” and “cure” are not equivalent. During the first
half of the twentieth century, the mortality due to tuber-
culosis was still high although many patients were saved
from dying thanks to the therapies available at that time.
The disease begun to be really “cured” with the arrival of
antibiotics that enabled the possibility to clean specifically
the infecting bacteria.
Molecular biology continues to be indispensable, but insuf-
ficient to overcome numerous biological and medical
problems.
Cancer, causes or consequences
After a century of thinking and research about cancer, the old
clinical idea that “cancer is a potentially malignant tumour”
remains valid and provides not much less information than
many sophisticated definitions. During the past half century,
our learning of the molecular, cellular and microenvironmen-
tal patterns involved in the biology of cancer has increased
almost exponentially and represents today an impressive cor-
pus of knowledge.
Different cell abnormalities, functional and structural,
genetic and/or epigenetic, have been associated with
cancer emergence and progression, but none of them
can give a pertinent explanation of the events, simulta-
neously “necessary” and “sufficient”, to provoke the
neoplastic transformation of cells. On the other hand,
we ignore the timing of cellular changes (i.e., somatic
mutations) or the sequence of events (i.e., the evolving
of cancer stem cells) giving rise to the critical malignant
phenotype. It is not surprising, since we are concerned
with a disease that can be lethal in a few months or
after one or more decades, or even never, that survivors
may die from a different pathology, unrelated to cancer.
This testifies to the enormous complexity of human
malignancies.
For more than a century, many causes and factors
have been proposed to account for cancer, often related
with the branch of biomedical research prevailing at the
time that those concepts were postulated. Successively
or simultaneously, cancer has been attributed to prob-
lems with metabolism, the dysfunction of some en-
zymes, weakness of the anti-tumour activity of the im-
mune system, a disordered process of cell differentia-
tion, an infection with oncogenic viruses, an aberrant
programming of normal genes, the activation of tumour
genes, the expression of genes involved in the positive
(proto-oncogenes) or negative (suppressor-genes) regula-
tion of cell growth, the unbalance of anti-apoptotic and
pro-apoptotic pathways in favour of the former, the fail-
ure of the homeostatic control of tissue-specific stem
cells, and, more recently, to genomic instability at the
origin of genomic aberrations. The list is, indeed, in-
complete but each one of these proposals bears part of
truth. The main difficulty in making a choice among the
suggested concepts of the origin of cancer lies in how
to discriminate causes that are upstream of the oncogen-
ic transformation from those which are in fact the con-
sequence of the cancer.
Recently, coincidental with the “genomic era”, the
following assertion was advanced [2]: “all cancers are
caused by somatic mutations; however, understanding of
the biological processes generating these mutations is
limited”. The genomic instability that underlines the
high rate of mutations found in many tumours supports
this statement, but its limitation probably results from
the fact that cancer is firstly a disease and as it stands
should be explored at different levels of complexity. I
would like, in the present paper, to reflect on some
major factors that, during the last 60 years, have be-
come accountable for cancer emergence and develop-
ment, including particularly, stem cell differentiation/
retrodifferentiation pathways that, in my opinion, seem
to play a non-negligible part in the initiation, progres-
sion or regression of malignancies.
Embryo-foetal characteristics of cancer
This subject, the resemblance between neoplastic and em-
bryonic tissues, that attracted the attention of biologists
for more than a century, has lost part of its previous in-
terest. However, it is worth remembering some facts, par-
ticularly because recent experience has revived interest in
the foetal patterns of gene expression in cancer as well as
on the activation of foetal genes in animal and human
malignancies.
A series of acquired biological capabilities characterising
the stepwise development of malignant tumours has
been proposed [3, 4] as “an organising principle for
rationalising the complexities of neoplastic disease”. They
include sustaining proliferative signalling, evading growth
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suppressors, resisting cell death, enabling replicative im-
mortality, inducing angiogenesis and activating invasion
and metastasis. These hallmarks of cancer constitute an
excellent compendium of the molecular basis that sustains
our present knowledge of the biology of malignant tu-
mours. Interestingly, most of them have their counterparts
in embryo-foetal development. Thus,
1. Embryos and neoplasms first appear as cellular popula-
tions with “self-sufficiency in growth signals” and a real
autonomy compared to the cellular dynamics and organi-
sation of the hosts.
2. Cell death regulation is essential for numerous life pro-
cesses. In fact, the mechanisms that control the different
types of cell death, apoptosis being the best studied, re-
main to be well delineated. Nevertheless, it is obvious that
in malignant as well as in embryo-foetal tissues, the bal-
ance between apoptotic and anti-apoptotic signals must be
in favour of the second in order to achieve their common
destiny, an increase in cellular mass.
3. Both ontogenic and neoplastic development progress
thanks to a high proliferative potential that mimics cell
immortality. Cancerous cells maintained in culture show
similar behaviour. This contrast with the short number of
divisions proper to normal adult cells before they enter
senescence and the dying processes. It is true that telome-
rase, the enzyme that adds telomere repeats onto chromo-
somes, plays an important role in the acquisition of cell
immortality. Telomerase is functional in the great majority
of malignant neoplasms but has also been demonstrated to
be fully active in all human foetal tissues examined and to
decline abruptly after birth [5].
4. To induce angiogenesis, it is a requisite for all growing
cell populations in order to supply the requirements of
nutrients and oxygen as soon as a nascent cell mass has
attained a critical size. This also occurs in developing
tumours and embryos.
5. The ability to invade nearby structures and to migrate far
from their place of origin is a property shared by both
malignant and embryonic cells. A remarkable case is pro-
vided by skin melanomas, the cells of which can spread to
distant organs. Similarly, normal melanoblasts, cells de-
rived from the neural crest, a primordial embryonic struc-
ture, colonise the skin and hair follicles of mammals dur-
ing the gestational period to later become differentiated
melanocytes and the potential source of oncogenic trans-
formation. When this occurs, melanoma cells utilise reg-
ulatory signals and pathways characteristics of embryo-
foetal development and regeneration [6].
An emerging hallmark, recently proposed [4], concerns the
classical observation of Warburg [7] that most tumours show
low respiration rates and, whenmetabolising glucose, produce
lactate at higher rates than do normal adult tissues. This led
him to conclude that damage to the respiratory process of
malignant growing cells and the adoption of a fermentative
pathway to derive energy necessary for survival were the
cause and the mechanism of cancer. Only much later, Villee
[8] did demonstrate significantly high aerobic glycolysis in all
human embryonic tissues of the gestational period studied.
That is, the pathway to derive energymetabolism is a hallmark
common to cancerous and embryo-foetal cells.
A different approach to the question of the relationship
between cancer and developmental biology was taken in
1945. Greenstein concluded from his studies that “tumours
tend to converge to common enzymatic patterns” and that in
certain cases, these patterns resemble those of foetal tissues
[9]. The question was brought up again in 1963 after the
discovery by electrophoretic and or immunodiffusion tech-
niques of an aldolase A of foetal type in soluble extracts of
rat hepatomas [10] and of a protein (alpha-fetoprotein) in the
sera of adult mice bearing chemically induced hepatomas [11].
The finding was confirmed in the case of human
hepatocarcinomas [12]. Soon later, the presence of another
foetal protein, called carcino-embryonic antigen, was demon-
strated in the serum of patients with colonic cancer [13, 14].
The possibility of revealing the presence of a tumour by the
single analysis of a serum sample opened a still active domain
of medical research and clinical practice in oncology, that of
“tumour markers.” It also focused the interest of oncologists
on embryo-foetal development and its role in the emergence
of malignant tumours (see review by Uriel [15]).
Unlike to the intensive work undertaken for decades to
elucidate the molecular basis of cancer, its comparative search
in embryo-foetal development was seldom undertaken. Re-
cent work from Spike et al. [16] has shown that a mammary
stem cell population, identified and characterised in late em-
bryogenesis, exhibits gene expression profiles with significant
similarities to basal-like breast cancer subtypes. Also, Ben-
Porath et al. [17] have found that histologically poorly differ-
entiated human tumours of various types show preferential
overexpression of genes normally enriched in embryonic stem
cells. In breast tumours, this embryonic cell-like signature was
associated with high-grade oestrogen-receptor-negative tu-
mours [17]. Again, a molecular switch that appears to turn
on some genes known as promoters of rapid growth in foetal
and early postnatal life is also reactivated in cancer cells [18].
Taken together, these observations confirm the impor-
tance of the foetal characteristics of cancer as a source of
useful information that can contribute to better under-
standing of the biology of cancer at molecular, cellular
and micro-environmental levels. For instance, it would
be very interesting to know the genomic profile of cells
during embryo-foetal development. It would not be sur-
prising to find significant analogies in the expression of
genes proper to malignant elements.
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Differentiation/retrodifferentiation pathways
The interest in cancer research for cell differentiation was a
consequence of the demonstration of the embryo-foetal prop-
erties associated with malignancies of different origin. Thus,
late in the 1960s, Pierce [19, 20] concluded that the target cell
of the majority of cancers was a pluripotent embryonic cell
(stem cell) and Potter [21, 22] considered that neoplasms were
the result of the interrupted differentiation of a population of
embryonic stem cells. A different, although not exclusive,
concept of oncogenic transformation was proposed by Uriel
[23, 24]. Such transformation can occur during the process of
cell rejuvenation (retrodifferentiation) that may affect normal
elements of many tissues following cell injuries of varied na-
ture. Uriel introduced the term of “retrodifferentiation” [23]1,
instead of that of “dedifferentiation”, in order to emphasise the
“stepwise and ordered character” of the process. The reversion
of adult elements towards foetal-embryonic states is thus con-
sidered as a broadly inverted sequence relative to that of
differentiation.
The impact of harming factors in the nucleo-cytoplastic
structures of the aggressed cells may have, at least, three dif-
ferent consequences: (a) the damage has been very faint, and
the natural resources of cell repair can restore the initial status
of the cell; (b) the injury has overcome the cell capability of
life maintenance, and the cell dies through necrotic or apopto-
tic processes; and (c) the cell disorder has been moderate, and
a third option is opened up—cell retrodifferentiation. The lat-
ter appears then as an alternative to the cell’s risk of suffering
irreversible deleterious changes. It enables cells, adult or stem
cells, to revert temporally towards younger stationary states
better adapted to stressing environmental conditions. The
change is advantageous because when cells differentiate, they
expend energy and bind information content to build new
structures and to develop new functions. On the contrary, cells
undergoing retrodifferentiation lose information content since
they self-simplify their structures and thereby evolve energy
that can be used to increase their growth potential. In other
words, differentiation is a negentropic process while
retrodifferentiation is an entropic one [24]. The latter is con-
sequently a thermodynamically favourable and less costly
change. The question is not merely academic, cells leaving a
stationary state and facing the alternative between the two bi-
directional pathways (differentiation vs retrodifferentiation)
will be, in the absence of differentiation impulses, naturally
inclined to revert through more immature states. This may
explain why neoplasms evolve, early or late, to phenotypes
of higher growth potential and malignancy. On the other hand,
the rejuvenation process of injured adult or stem cells contrib-
utes to increase the number of dividing cells of a tissue and
thus the risk of cancer emergence as a consequence of lifestyle
factors, including those derived from an aggressive cancer
treatment (see also “The future of cancer care”). According
to this, the part played by the randomness versus the lifestyle
(2/3 to 1/3) in cancer [26] may change or even be reversed by
the extra-cell divisions induced after cell injury. One property
often associated with immature cells, either normal or cancer-
ous, undergoing retrodifferentiation is their ability to bind and
to internalise alpha-fetoprotein (AFP) via the expression of
specific receptors [27]. Another example of how normal and
neoplastic non-stem cells may evolve further in the way of
retrodifferentiation is provided by the work of Chaffer et al.
Another example of how normal and neoplastic non-stem
cells may evolve further in the way of retrodifferentiation is
provided by the work of Chaffer et al. [28]. Studying cultures
of normal and neoplastic mammary epithelial cells (HMECs),
they could demonstrate that these differentiated elements can
spontaneously revert to a stem cell-like state.
The preferential evolution of cells, normal or cancerous,
towards retrodifferentiated states when subjected to damaging
or stressing agents was, to my knowledge, never considered,
neither in the elaboration of the current concept dealing with
the role of stem cells in oncogenesis, nor in the pivotal prob-
lems associated with cancer heterogeneity and regenerative
medicine. For the latter, it may be a real difficulty able to
disturb, to slow down or to arrest the terminal differentiating
steps necessary for successful tissue repair or organ regenera-
tion (see also below under “normal and cancer stem cells”)
Normal and cancer stem cells
Studies on stem cells (SCs) have received considerable atten-
tion in the last decade related with both cancer development
and regenerative medicine. Stem cells are currently
characterised by their ability to self-renew indefinitely and to
differentiate or, as commented above, to retrodifferentiate into
a variety of specialised cell types. The terminology used to
describe SCs is slightly complex due to the fact that it has been
established, either on a conceptual basis (totipotent “embry-
onic stem cells”; unipotent, pluripotent or multipotent “adult
stem cells”), or on an operational basis such as those referring
to the tissue from whence they arise (mesenchymal-, skin-,
intestinal-, hair follicle-stem cells, etc.). A great impulse for
stem cell studies was obtained by the discovery of the method
to produce pluripotent stem cells (iPSCs) from murine adult
somatic cells [25]. This was initially obtained by the introduc-
tion of four specific genes and later by other genetic manipu-
lation of cells of different origin, including human. These
procedures that avoid the controversial use of human
1 More recently, the term “reprogramming” has been used to describe the
induction, from adult or adult stem cells, of pluripotent stem cells (iPSCs)
with high capacity to differentiate in vitro and in vivo [25]. Nevertheless,
reprogramming means to program again. Perhaps the term
“retroprogramming” could be used with the same meaning as
“retrodifferentiation”.
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embryonic stem cells for experimental purposes have consid-
erably facilitated studies on regenerative medicine.
Numerous different phenotypes of normal stem cells have
been characterised and isolated in a variety of adult tissues
from invertebrates to humans. These “tissue-specific stem
cells” are frequently grouped forming sort of “niches” in the
vicinity of, and in close interaction with, a microenvironment
of normal adult resting cells. Normal stem cells play an im-
portant role in physiological processes accompanying the re-
newal, maintenance or repair of tissues and cellular structures.
One important point to be elucidated is why tissue-specific
stem cells, provided with an assumed high growth potential,
remain in a stationary state.We ignore the question of what are
the signals or the microenvironmental conditions that drive
these inert stem cells towards more differentiated or
retrodifferentiated states.
More recently, a new interest in the stem cell area of re-
search has come from the so-called cancer stem cell (CSC)
hypothesis. This hypothesis is based on the finding within
tumours of malignant cells with the characteristics of adult
stem cells and suggests that they derive from the neoplastic
transformation of tissue-specific normal stem cells from dif-
ferent origin and probably represent the true drivers of cancer
development, particularly of solid tumours (see reviews by
Nguyen et al. And Iqbal et al. [29, 30]). Cancer stem cells
have been characterised and isolated from human malignan-
cies. Most of the information supporting the CSC hypothesis
has been obtained; however, from experiments done after
transplantation of isolated CSCs into immune-suppressed or
immune-deficient mice. As discussed below, the simple fact of
isolating CSCs from tumour biopsies already implies a harm-
ful process. There is a great probability that cells having es-
caped alive from such treatments have already experienced
damage able to induce differentiation/retrodifferentiation
events and/or to facilitate genomic or other nucleocytoplastic
changes that could lead sooner or later to the emergence of
newmalignant clones not present in the original tumour. Also,
the growth of human CSCs in immune-depressed mice may
contribute, via selection pressure of different homeostatic con-
ditions, to unnatural erratic developments. Analogous restric-
tions may be addressed to assays performed using long-time
established lines of mouse or human tumours. The conclu-
sions derived from such experiments cannot be accepted with-
out caution. In fact, recent work in this area has shown that the
CSC concept is more complex than initially considered. Thus,
examples have been found in the existence of abnormal clones
of cells with mutations of known oncogenic potential that,
nevertheless, does not manifest malignancy for years. It has
been suggested applying to them the term “neoplastic stem
cells” and to restrict the term “cancer stem cells” to those
generating fully malignant clones [31].
The CSC concept, although controversial [32], is of great
interest because it brings into focus the pivotal role of cell
differentiation in neoplastic transformation and/or in the fur-
ther evolution of transformed cells giving rise to the emer-
gence of new clones of cells whose eradication could be de-
terminant for a successful cancer treatment [33]. In spite of the
criticisms that can be made of this concept, stem cells and cell
differentiation have become and should continue to be major
topics in cancer research.
Cancer heterogeneity
The heterogeneity of tumours was already well known and
characterised by morphologic criteria thanks to the careful
work of histopathologists throughout the twentieth century.
In 1976, Nowell proposed, for the first time, that progression
of tumours might result from acquired genetic instability with-
in the original clone and the accumulation of genomic alter-
ations that could favour the growth of cloned variants with
survival advantage [34]. The possibility of intra-tumour het-
erogeneity was also anticipated on the basis of differences
encountered between rat liver regeneration and oncogenesis
[15] (see also Fig. 1). The presence of multiple clones derived
from a single tumour was attributed, at least in part, to the level
of the differentiation step where the neoplastic transformation
took place or remained stationary.
After the sequencing of the human genome in 2001, there
has been interest in genomic analysis of tumours with the idea
of characterising somatic mutations that occurred during can-
cer emergence and progression and then developing drugs or
procedures better adapted to the treatment of a given tumour
as well as discovering new biomarkers with higher discrimi-
nating ability (for reviews, see [35, 36]). Unfortunately, the
recent demonstration of the heterogeneity of the genomic pro-
file in different areas of a single malignancy and between the
original tumour and its metastasis has tempered the hope of
rapid progress in personalised treatments. The same limita-
tions concern the development of treatments based on bio-
marker’s data obtained from a single biopsy [37]. Genomic
profiles and biomarkers can also change with the evolution in
time of the clones derived from the original tumour, due in
part to the selection pressure resulting from the use of different
treatments.
Nevertheless, the awareness of intra- and inter-tumour het-
erogeneity is rapidly having a considerable impact in current
cancer research because it represents a major contribution to
the biology of cancer and in medical practice due to its con-
sequential effects on cancer management (see reviews by
Russnes et al. and Sonner et al., 2012 [36]. The multiplicity
of samples that need to be analysed at one time from a single
patient and at several times during the evolution of the pa-
tient’s tumour makes the development of adequate drugs, or
the choice of other relevant treatments, an enormous and, at
present, almost insurmountable task [38]. Moreover, the
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already elevated costs associated with cancer therapies will be
further increased by the eventual use of such procedures.
Regeneration versus neoplastic transformation
The irreversibility of the adult cell state has in the distant past
been a firmly held opinion by many embryologists. Today, as
experimental evidence has accumulated, there is no formal
argument against the assumption that embryonic reversion is
potentiality inherent to all somatic cells of an organism as long
as their genetic information content is preserved. The ability to
revert may, however, vary among cells of different organisms
or from one cell species to another in the same individual [39,
40]. On the other hand, varied observations emphasise the
central role of retrodifferentiation in regeneration, wound
healing and neoplastic growth (Fig. 1) [24, 41].
The link between regeneration and cancer was postulated
in 1935 [42], and the topic periodically revisited since then. In
mammals, both processes can start as a response to cell or
tissue injuries of external (e.g. physical harm, cytotoxic
agents, viruses) or internal (hormones, ageing) origin. Both
are characterised by the presence of immature growing cells:
tissue-specific stem cells in regeneration or tissue repair and
cancer stem cells in neoplasms. Both processes progress,
among other events, by the gene expression of foetal type
proteins and enzymes. The origin of these stem cells remains,
nevertheless, uncertain. The question has been raised whether
they preexist in significant quantities as normal tissue compo-
nents (stem cell niches) or are induced by cell injury and
neoplastic transformation. On the other hand, the presence of
stem cells in regenerating and neoplastic tissues could be also
inferred from the hypothesis [24] that cell injury triggers
retrodifferentiation and consequently a process of cell rejuve-
nation with the appearance of stem cells of a different degree
of immaturity.
This alternative has recently found experimental con-
firmation in vitro and in vivo. Thus, Chaffer et al. [28]
have identified “a subpopulation of basal-like human
mammary epithelial cells that spontaneously dedifferen-
tiate into stem-like cells”. Moreover, neoplastic transfor-
mation enhances spontaneous conversion, so that adult,
non-stem cancer cells give rise to cancer stem cells
in vitro and in vivo. Also, the work of Abad and co-
workers [43] has produced evidence that teratomas from
multiple organs emerge in mice after transitory induc-
tion of four transcription factors concomitant with the
presence of circulating iPSCs showing characteristics
very close to those of embryonic stem (ES) cells. This
experiment demonstrates again the possibility of in vivo
retroprogramming of adult cells.
The relationship between tissue repair, regeneration and
cancer development represents a serious challenge for future
progress in regenerative medicine because, as discussed
above, terminal steps of cell differentiation necessitate the
expenditure of energy and bound information content to ac-
quire their final structures and functions characteristic of op-
erational adult tissues and organs. This process competes with
the expected increase of rejuvenation potential of cells ap-
proaching the adult state.
Fig. 1 Schematic representation of hypothetical neoplastic development
arising in adult tissues. A mature liver parenchymal cell enters
retrodifferentiation under hepatic injury. The initial transition follows
distinct pathways: either it can be “counter balanced” by a process of
re-ontogeny which restores the phenotypic properties of the mature cell
(regeneration) or it can persist “unbalanced” and even progress, the cell
travelling through various stages of “rejuvenation” until the neoplastic
transformation takes place. Dashed arrows indicate alternative routes of
stem cells that emphasise the plasticity of the hypothetic model. Several
phenotypes of malignant clones may coexist in the same tumour
(reproduced from Uriel [15])
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The cancer treatment paradox and the strategy
of killing cancer cells
The comparative analysis of past and current anti-cancer treat-
ments and the accumulated knowledge after more than a cen-
tury of research and medical practice in cancer leads to a
paradoxical situation. There is agreement on the major exter-
nal causes leading to the emergence of human malignancies:
ionising radiations, ultraviolet light, environmental pollutants
released by vehicles and industrial processes, pesticides, to-
bacco or alcohol abuse, etc. Beyond a given threshold of con-
centration or of cumulative effect, they become potentially
oncogenic due to their common ability to damage cells by
contact, inhalation, ingestion or other ways. Regenerative cy-
cles, involving tissue-specific stem cells, in response to cell
wear or ageing, occur regularly in many tissues, such as skin,
respiratory and digestive tracts and can be the target of onco-
genic transformation. Cell injury and cell damage, either from
external or internal sources, are concomitant with all these
events and seem to be a requisite for cancer initiation. There-
fore, the current treatments (surgical eradication, radio-, che-
mo-, immune- and hormone-therapies) supposed or intended
to “cure” cancer have, as their main and common purpose, the
killing or the removal of the largest number of cancer cells. In
other words, the agents that may initiate malignant tumours
and those intended to treat them are both essentially cell injury
agents. That is the paradox.
If the reasoning outlined above (“Differentiation/
retrodifferentiation pathways”, “Normal and cancer stem cells”
and “The cancer treatment paradox and the strategy of killing
cancer cells” sections) is correct, cell injury can entail
differentiation/retrodifferentiation processes that preserve the
survival of some of the aggressed cells, but puts them in a state
of genetic instability, then cancer treatments that damage cells
may become double-edged weapons. On one hand, they de-
stroy malignant cells while on the other hand, they can injure
and, consequently, induce divisions and mutational changes in
cells that have escaped previous treatments. This may involve
normal and cancer stem cells, dormant micrometastasis or,
even, healthy active and resting adult cells of the same or dif-
ferent tissues. In all cases, there is the risk of the genesis, via
differentiation/retrodifferentiation stimulus, of new malignant
clones with different sensitivity to the previously used anti-
cancer agents. Tumours of different histological origin, partic-
ularly of the hemo-poietic system, may also emerge for the
same reason. The latter have been observed and found statistical
confirmation, in cases of acute myeloid leukaemia (AML) fol-
lowing breast cancer treatment with chemical drugs. Contrary
to the preceding findings [44], recent studies have pointed out
the increased risk for both AML andmyelodysplastic syndrome
post-radiation treatment [45]. The benefits awaited and often
really gained with the use of cytotoxic agents in cancer care
may, thus, become counter-productive.
The great intra- and inter-heterogeneity, both spatial and tem-
poral (for a review, see Russner et al. [36]) of human tumours, in
long-term cancer care and the use of successive treatments, most
of them cytotoxic, are becoming lethal for a high proportion of
malignant elements. At the same time, there is increasing prob-
ability of cancer progression that can lead to more aggressive
clones of tumour cells and finally to the terminal phase of the
disease.
In face of this situation, one is tempted to suggest that we
have very little chance, if any, of really “curing” the great
majority of cancers, particularly those of solid tumours, as
long as the main, if not the sole, treatment strategy continues
to be that of killing cancerous cells.
The future of cancer care
Should we infer from these considerations that the present
therapies for fighting cancer should be stopped? Certainly
not, because of the real progress in the choice and use of drugs
and radiation to target tumours and, above all, because many
comparative studies have proven that current approaches effi-
ciently prolong the survival of patients with a large variety of
tumours or even to make cancer a chronic disease. Also, we
know better than in the past how to soften and/or to prevent
the collateral effects of current treatments although heart dam-
age from cancer chemotherapy and/or radiation continue to be
a serious problem in clinical practice [46]. On the other hand,
we have not found anything to replace such therapies. In the
history of medicine, a paradigmatic therapy was never aban-
doned before another one had proven its unquestionable ad-
vantage. This is the challenge for future cancer care. In any
case, this should not be an impediment to looking insistently
for different approaches, and among them are the following.
Tumour reversion
Is neoplastic transformation an unchangeable event? The pos-
sibility to reverse the cancer status has fascinated oncologists
for more than a century. Evidence of phenomenon in plants
was first supported by the pioneer work of Armin Brawn [47].
Later on, in his excellent review devoted to this topic [48], he
extended the analysis of tumour regression to several animal
species, man included. Two typical examples are the induced
differentiation of mouse teratocarcinoma into multiple mature
tissues and the spontaneous regression of childhood neuro-
blastomas. An experiment providing evidence that the gene
information present in a cancer nucleus may be not irrevers-
ible was performed by McKinell et al. [49].
Adenocarcinomas were induced in a triploid line of frogs.
Nuclei from the tumour cells were injected into enucleated
normal frog eggs. A significant number of triploid swimming
apparently normal larvae or tadpoles were produced. It
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appears from these studies that despite serious genomic im-
balance, malignancies may be completely reversible and led
Armin Brawn to conclude that “there is certainly no longer
any good reason for believing that nuclear gene function in a
cancer cell is beyond hope of correction…” [48].
Subsequently, studies at the microenvironmental and molec-
ular levels have confirmed the possibility of the experimental or
therapeutic reversion of the malignant status. Several laboratories
interested in the development of normal and neoplastic cells used
matrigel tridimensional cultures of cells isolated from breast and
other human cancers to analyse tumour reversion. They arrived
at the conclusion that “the correction of 1 or 2 signalling defects
can revert tumour cells to a normal phenotype, both in vivo and
in vitro” (see review by Kenny and Bissell [50]).
In humans, the reversion of malignancies of the hemopoi-
etic system has yielded the best clinical benefits. Thus, treat-
ment of acute promyelocytic leukemias with retinoid acid
alone or in combination with chemotherapy may result in
complete induction of differentiation of promyelocytes to ma-
ture cells [51]. Relapses after a short period of remission were,
however, frequently noticed.
A different approach was undertaken by the group of Amson
and Telerman. The purpose of their research was to understand
the molecular program of tumour reversion and its clinical appli-
cation. They first isolated revertant cells from breast and other
tumours followed by the differential analysis of gene expression
between the parental cancer cells and the derived revertants [52].
At least 300 genes were implicated in the reversion process.
Among them, it appeared that translationally controlled tumour
protein (TCTP) is a key gene that needs to be switched off before
a malignant cell proceeds to revert [53, 54].
The rarity of spontaneous or induced regression of human
cancers and the small number of laboratories currently in-
volved in these studies should not be a reason to neglect this
approach. On the contrary, coordinated research work in this
area at molecular, cellular and micro environmental levels
should be encouraged for the benefit of both the insight into
our knowledge of the biology of cancer and the possible even-
tual successful treatment of the disease.
Cell differentiation management
This is a corollary of the preceding comments. As discussed
above, normal stem cells moving along differentiation//
retrodifferentiation pathways are currently derived under strict
homeostatic conditions in renewing, expanding and
regenerating tissues (skin, hemopoietic system, liver, etc.).
Both pathways are also involved in cancer development and
progression and could represent the basis for an alternative
cancer treatment different from that of cell-killing therapies
currently used to fight malignant tumours [52]. Unfortunately,
to date, we do not have enough information on the molecular
events, the forces involved and the ways to manage cell
differentiation and its alternative way, retrodifferentiation or
retroprogrammation. Research work in this area, which can be
extended to that of tissue regeneration in lower and higher
animals, would deserve much attention and should be under-
taken because of the potential value if proved successful.
Either tissue-specific normal stem cells or cancer stem cells
possess the ability to divide, differentiate or retrodifferentiate
[4]. It is of greatest importance to know what homeostatic
forces may drive those cells to full differentiate or at least to
attain stationery states. It could give the opportunity of
neutralising the growing activity of tumours, without the
harmful effects derived from the use of cytotoxic drugs and
ionising radiations. It might also help to elucidate the serious
problems encountered to progress in regenerative medicine.
Immunotherapy and cancer
The harnessing of patient’s own immune system to fight cancer
has attracted the attention of the biomedical word for more than a
century. That an immune response to the emergence of cancerous
cells exists in animals andmen is generally accepted. Great prog-
ress has been made on elucidating such an anti-tumour response
and the way to activate it with a variety of procedures. Neverthe-
less, the results obtained in clinical practice were until now rather
modest, although some recent successful clinical trials have giv-
en hope of promise for the future [56]. The reasons underlying
the lack of greater success have beenwell analysed and explained
in a publication from the Society for Immunotherapy of Cancer
(SITC) [55] that summarises the discussions and recommenda-
tions gained at an “Immunotherapy Submit”with representatives
from immunotherapy organisations of different countries. Sever-
al hurdles were identified that impede the successful translation
of immunotherapy into clinical practice. Among them are as
follows: (a) the limitations encountered by the use of animals
as preclinical models; (b) the complexity of cancer due to cell
heterogeneity and its translation into different clones with differ-
ent target characteristics; (c) the variability of the anti-tumour
response according the status of the patients (age, previous treat-
ments, tumour progression, etc.); (d) the lack of definitive bio-
markers of immune response permitting discrimination of what,
in a case of tumour regression, is due to immunotherapy and
what to previous or simultaneous unrelated treatments (chemo-
therapy, radiotherapy); and (e) the risk of over-activation of the
response to immunotherapy, causing auto-immune harmful
reactions.
The use of immunotherapy as a potential weapon against
malignancies can be criticised because this kind of treatment
belongs to the group of cell-killing therapies. Nevertheless,
the fine targeting of cancerous cells via stimulation of the
immune system to produce responses against cancer cells
should, in contrast to chemotherapy or radiotherapy, exclude
from the cytotoxic effects those normal mature or stem elements
that are unrelated to cancer. On the other hand, considering our
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present knowledge of cancer biology and the current status of
cancer care as well as the recent popularity of personalised treat-
ments, immune-based cancer therapies deserve greater attention
as a possible new and helpful frontier in tumour treatment. Last
but not least, the strong relationship between cancer development
and the immune response calls for cooperative studies of immu-
nity and cancer biology. It is well known that life is a matter of
DNA but survival depends on a well-functioning immune sys-
tem. Its failure, particularly in cancer patients, triggers rapid de-
terioration. In fact, progress in cancer knowledge and treatment is
probably indebted to progress in cancer immunity. This evidence
should be sufficient to justify and stimulate active research work
in this area.
Concluding remarks
Significant progress was made over the last 60 years in the
knowledge of cancer biology and treatment of the disease. How-
ever, over the same period of cancer research and clinical practice
the ultimate “secret” leading to “cure” of malignant tumours has
not been found. This is not a single case in modern medicine in
the last 50 years.
Thanks to the advances in genomics we know, and it is very
important, that sets of spontaneous or induced mutations af-
fecting key genes are probably pivotal in cancer initiation [2].
Once again, great hopes of future advances in cancer manage-
ment have been associated with this recent discovery. Unfor-
tunately, one might anticipate that if developed alone this new
approach would not clear up, at least for the short or middle
term, the question of when, why and how one or several nor-
mal cells become a malignant neoplasm. Different and still
ignored causes or mechanisms of tumour emergence and pro-
gression will, probably, be found in the future. Also, the find-
ing of advanced and specific markers for cancer screening
might be expected.
Although cell-killing therapies have become paradigmatic
in fighting cancer progression, it seems imperative to open
new ways of research and to activate underestimated ones.
Also, imperative is to continue persuading human populations
and governmental agencies that the best line to fight cancer
remains avoidance of all external and internal agents contrib-
uting to tumour incidence. Among them, long-term and re-
peated cell injuries are probably the primary accident in the
chain of events leading to oncogenesis. All other recourses,
although indispensable today, are long, distressing, costly and
uncertain.
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